CEO Emily Leproust Sells $56.3M of Twist Bioscience Stock Under 10b5-1 Plan
TWST has more than doubled off its 52-week low of $23.3.
Summary
Twist Bioscience CEO Emily Leproust sold $56.3 million of stock on September 17 under a pre-existing 10b5-1 plan, exceeding the $44.7 million previously noticed. The sale was funded by exercising options at $8.82 and $26.66.
Key Events · Ownership and Investor Activity · TWST
-
CEO Sells $56.3M in Stock
Emily Leproust sold 356,546 shares for $56,330,724.19 at prices between $151.46 and $163.39 on September 17, 2026.
-
Sale Exceeds Prior Notice
The actual sale value exceeded the $44.7 million Form 144 intent filed the same day by approximately $11.6 million.
-
Options Exercised at Deep Discount
Leproust exercised 208,708 options at strike prices of $8.82 and $26.66, acquiring shares worth $4.2 million at exercise cost before selling.
-
10b5-1 Plan Execution
All transactions were executed under a Rule 10b5-1 trading plan adopted June 15, 2026, indicating the sale was pre-planned rather than discretionary.
Analysis · TWST · Life Sciences
On September 17, 2026, CEO Emily Leproust executed a pre-planned sale of 356,546 shares for $56.3 million at prices ranging from $151.46 to $163.39. The transaction was part of a Rule 10b5-1 trading plan adopted June 15, 2026, and followed a Form 144 filed the same day indicating intent to sell $44.7 million. Actual proceeds exceeded the noticed amount by roughly $11.6 million, reflecting the stock's continued strength near its 52-week high. The sale was funded by exercising 208,708 options at strike prices of $8.82 and $26.66, locking in substantial gains. While the transaction is pre-planned and therefore not a signal of insider pessimism, the magnitude — over half a percent of the company's market capitalization — makes it a notable liquidity event for shareholders.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.4% of the 1495 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TWST was trading at $165.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.9B. The 52-week trading range was $23.30 to $170.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.